ArticleAmerican journal of cancer research2025
Clinical predictors for liver function impairment and post-embolization syndrome following transcatheter arterial chemoembolization in primary hepatic carcinoma patients: a retrospective study.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The clinical utility of serum prealbumin levels as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: a meta-analysis of 2,996 patients.Frontiers in oncology · 2026Pooled it
- Analysis of risk factors for post-transarterial chemoembolization syndrome in patients with liver cancer: a systematic review protocol.Systematic reviews · 2026Article
- Dexamethasone and N-acetylcysteine for the prevention of post-embolization syndrome following transarterial chemoembolization in hepatocellular carcinoma: a systematic review and network meta-analysis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify clinical predictors of liver function impairment and post-embolization syndrome (PES) following transcatheter arterial chemoembolization (TACE) in patients with primary hepatic carcinoma (PHC), to facilitate risk stratification and improve clinical outcomes.
methodsA retrospective study was conducted on 549 PHC patients who underwent TACE at Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University from June 2020 to January 2024. Data on demographics, liver function, imaging findings, and TACE regimens were collected. Multivariate Logistic regression analysis was employed to identify the independent risk factors for liver function impairment and PES. The predictive performance of these factors was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsAmong the 549 PHC, 61.93% (340/549) developed liver function impairment and 26.96% (148/549) experienced PES after TACE. ROC analysis indicated that alcohol consumption, cirrhosis, liver function grade, and TACE frequency demonstrated predicted value for liver impairment (AUCs: 0.565-0.619) and PES (AUCs: 0.581-0.656). Multivariate logistic regression identified neutrophils (OR=2.349, P=0.001), prealbumin (PA) (OR=1.674, P=0.028), liver function grade (OR=3.135, P<0.001), alcohol consumption (OR=0.296, P<0.001), cirrhosis (OR=0.528, P=0.005), and TACE frequency (OR=0.482, P=0.001) as independent predictors for liver impairment; For PES, alcohol consumption (OR=1.959, P=0.003), body mass index (BMI) (OR=0.288, P<0.001), albumin (ALB) (OR=0.384, P=0.005), PA (OR=0.288, P<0.001), and ECOG score (OR=0.527, P=0.006) were identified as the independent predictors, whereas liver function grade (P=0.287) and TACE frequency (P=0.634) were not. Nomograms based on these predictors demonstrated good discriminative ability (AUC=0.854 for liver impairment; AUC=0.826 for PES) and satisfactory calibration (P>0.05), with consistent performance in both training and validation cohorts (AUC: 0.852-0.854 for liver impairment; 0.820-0.843 for PES).
conclusionKey clinical variables, including alcohol consumption, cirrhosis, and specific biochemical markers, are significantly associated with liver function impairment and PES following TACE in PHC patients. These findings support the development of individualized treatment strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.